Asia-Pacific migraine treatment market is projected to register a CAGR of 14.7% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027
Market Segmentation:
Asia-Pacific Migraine Treatment Market, By Types of Migraine (Episodic, Migraine with Aura, Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/Prophylactic Treatment, Non-Pharmacological Therapies, Devices), Route of Administration (Oral, Parenteral, Nasal Sprays, Others), Product Type (Prescription, Over the Counter), Type (Branded, Generic), End User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), Country (Japan, China, South Korea, Australia, India, Singapore, Thailand, Malaysia, Indonesia, Vietnam, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of the Asia-Pacific migraine treatment market are:

- Growing female population
- Rising awareness programs
Market Players:
The key market players for Asia-Pacific migraine treatment market are listed below:

- Eli Lilly and Company
- Amgen Inc
- Eli Lilly and Company
- GlaxoSmithKline plc
- Novartis AG
- Bayer AG
- Allergan
- Abbott
- AOBiome
- AstraZeneca,
- Bausch Health Companies Inc
- Boehringer Ingelheim International GmbH
- Catalent, Inc
- Dr. Reddy's Laboratories Ltd
- Lundbeck
- Merck Sharp & Dohme Corp (A Subsidiary of Merck & Co., Inc)
- Pfizer Inc
- Otsuka Pharmaceutical Co., Ltd (A Subsidiary of Otsuka Holdings Co., Ltd.)
- Sun Pharmaceutical Industries Ltd